Penumbra Getting Closer To Key Technical Benchmark
On Monday, Penumbra got an upgrade to its Relative Strength (RS) Rating, from 63 to 75.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks compares to the rest of the market.
History shows that the market's biggest winners typically have an RS Rating of above 80 in the early stages of their moves. See if Penumbra can continue to show renewed price strength and clear that threshold.
Penumbra is working on a consolidation with a 320.10 entry. See if the stock can clear the breakout price in heavy volume.
Earnings grew 170% last quarter, up from 0% in the prior report. Revenue also increased, from 23% to 75%.
The company earns the No. 17 rank among its peers in the Medical-Products industry group. Bio Rad Labs and Edwards Lifesciences are also among the group's highest-rated stocks.